Administration and patient-incurred costs associated with opioid agonist treatment in Norway

References

• Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta‐analysis of cohort studies. Addiction. 2011;106(1):32–51.
   PubMed Web of Science ®Google Scholar
• Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(50-51):1445–1452.
   PubMed Web of Science ®Google Scholar
• Bukten A, Skurtveit S, Gossop M, et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2012;107(2):393–399.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, McKenzie M, Rich JD. Opioid addiction and incarceration: an overview. Med Health R I. 2007;90(5):157–158.
   PubMedGoogle Scholar
• Kelty E, Hulse G. Morbidity and mortality in opioid dependent patients after entering an opioid pharmacotherapy compared with a cohort of non-dependent controls. J Public Health. 2018;40(2):409–414.
   Web of Science ®Google Scholar
• Norway Drug Report 2018. European Monitoring Centre for Drugs and Drug Addiction; 2018.
   Google Scholar
• Aas CF, Vold JH, Skurtveit S, for the INTRO-HCV Study Group, et al. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Subst Abuse Treat Prev Policy. 2020;15(1):68.
   PubMed Web of Science ®Google Scholar
• Helse- og omsorgsdepartementet. Forskrift om legemiddelassistert rehabilitering (LAR-forskriften). [Internet]. 2009. [cited 2021 May 31]. Available from: https://lovdata.no/dokument/SF/forskrift/2009-12-18-1641.
   Google Scholar
• Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59(10):1411–1419.
   PubMed Web of Science ®Google Scholar
• Strathdee SA, Beyrer C. Threading the needle—how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373(5):397–399.
   PubMed Web of Science ®Google Scholar
• Waal H, Bussesund K, Clausen T, et al. Statusrapport 2018: LAR i rusreformenes tid. SERAF; 2018.
   Google Scholar
• Lobmaier P, Skeie I, Lillevold P, et al. Statusrapport 2020: LAR behandling under første året med Covid-19 pandemi [Internet]; 2021. Available from: https://www.med.uio.no/klinmed/forskning/sentre/seraf/publikasjoner/rapporter/2021/seraf-rapport-nr-4-2021-statusrapport-2020.pdf.
   Google Scholar
• Onuoha EN, Leff JA, Schackman BR, et al. Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review. Value Health. 2021;24(7):1068–1083.
   PubMed Web of Science ®Google Scholar
• Waal H, Bussesund K, Clausen T, et al. Statusrapport 2017: LAR 20 år Status, vurderinger og perspektiver. SERAF; 2018.
   Google Scholar
• Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315–326.
   PubMed Web of Science ®Google Scholar
• Muruganandam P, Shukla L, Sharma P, et al. Too little dose – too early discontinuation?’—effect of buprenorphine dose on short term treatment adherence in opioid dependence. Asian J Psychiatr. 2019;44:58–60.
   PubMed Web of Science ®Google Scholar
• Kumari S, Manalai P, Leong S, et al. Factors associated with non-adherence to buprenorphine-naloxone among opioid dependent African-Americans: a retrospective chart review: therapeutic adherence to buprenorphine-naloxone. Am J Addict. 2016;25(2):110–117.
   PubMed Web of Science ®Google Scholar
• Bandawar M, Kandasamy A, Chand P, et al. Adherence to buprenorphine maintenance treatment in opioid dependence syndrome: a case control study. Indian J Psychol Med. 2015;37(3):330–332.
   PubMedGoogle Scholar
• Kinsky S, Houck PR, Mayes K, et al. A comparison of adherence, outcomes, and costs among opioid use disorder medicaid patients treated with buprenorphine and methadone: a view from the payer perspective. J Subst Abuse Treat. 2019;104:15–21.
   PubMed Web of Science ®Google Scholar
• Pizzicato LN, Hom JK, Sun M, et al. Adherence to buprenorphine: an analysis of prescription drug monitoring program data. Drug Alcohol Depend. 2020;216:108317.
   PubMed Web of Science ®Google Scholar
• Tiberg F, Johnsson M, Jankunec M, et al. Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions. Chem. Lett. 2012;41(10):1090–1092.
   Web of Science ®Google Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder. JAMA Intern Med. 2018;178(6):764–773.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Dunlop AJ, Haber PS, et al. Patient-Reported outcomes of treatment of opioid dependence With weekly and monthly subcutaneous depot vs. daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw Open. 2021;4(5):e219041.
   PubMed Web of Science ®Google Scholar
• Statens Legemiddelverk. Legemiddelvisning: Buvidal – 32 mg [Internet]. www.legemiddelsok.no. [cited 2021 Nov 19]. Available from: https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=d5b39585-9b41-48fc-a3a7-83732f28ce9b&searchquery=buprenorphin&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=1.
   Google Scholar
• Statens Legemiddelverk. Legemiddelvisning: Buvidal – 64 mg [Internet]; 2021 [cited 2021 Nov 19]. Available from: www.legemiddelsok.no. https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=77430dba-82f5-4764-842b-2f20f1f72c11&searchquery=buprenorphin&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=1.
   Google Scholar
• Statens Legemiddelverk. Legemiddelvisning: suboxone – 8 mg/2 mg [Internet]. www.legemiddelsok.no. [cited 2021 Nov 19]. Available from: https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=29ac0b83-2a5b-4379-9993-25c3a597f10c&searchquery=buprenorphin&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=1.
   Google Scholar
• Statens Legemiddelverk. Legemiddelvisning: Suboxone - 16 mg/4 mg [Internet]; 2021 [cited 2021 Nov 19]. Available from: http://www.legemiddelsok.no. https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=cff531fa-58df-4424-ab03-686df8cbcbce&searchquery=buprenorphin&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=1.
   Google Scholar
• Statens Legemiddelverk. Legemiddelvisning: Buprenorphine Sandoz - 8 mg [Internet]. www.legemiddelsok.no. [cited 2021 Nov 19]. Available from: https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=16e8b6f7-9d1b-4378-98b8-58d9390e0fe9&searchquery=buprenorphin&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=1.
   Google Scholar
• Statens Legemiddelverk. Legemiddelvisning: Metadon Martindale Pharma – 2 mg/ml [Internet]; 2021 [cited 2021 Nov 19]. www.legemiddelsok.no. Available from: https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=f2bf4c87-3197-459a-9ed9-e61ffe4b3497&searchquery=metadon&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=1.
   Google Scholar
• Apotekavtalen bilag 1: Avtale om opgjør for LAR-legemidler og LAR-tjenester i apotek Internet]. Aftale mellom De regionale helseforetak i Norg og Norges Apotekerforenin; 2019 [cited 2021 Jan 27]. Available from: http://www.apotek.no/Files/Apotekregelverk/Rundskriv/Andre/20190101%20LAR-avtalen%202%20av%204.pdf.
   Google Scholar
• Den norske legeforening. Normaltariff for fastleger og legevakt (2019–2020) [Internet]; 2019 [cited 2021 Jan 27]. Available from: https://normaltariffen.legeforeningen.no/asset/pdf/Fastlegetariffen-2019-2020.pdf.
   Google Scholar
• The Norwegian Medicines Agency. Enhetskostnadsdatabase [Unit cost database] [Internet]; 2021. Available from: https://legemiddelverket.no/offentlig-finansiering/dokumentasjon-for-metodevurdering/enhetskostnadsdatabase.
   Google Scholar
• Utlevering av LAR legemidler: Nasjonal godtgjørelse for utlevering i apotek. Helsedirektoratet; 2017.
   Google Scholar
• Norwegian Medicines Agency (NoMA). Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals [Internet]; 2021 [cited 2022 Jun 16]. Available from: https://legemiddelverket.no/Documents/English/Public%20funding%20and%20pricing/Documentation%20for%20STA/Guidelines%2018.10.2021.pdf.
   Google Scholar
• Oderda G, Lake J, Rudell K, et al. Economic burden of prescription opioid misuse and abuse: a systematic review. J Pain Palliat Care Pharmacother. 2015;29(4):388–400.
   PubMedGoogle Scholar
• Muller AE, Skurtveit S, Clausen T. Performance of the WHOQOL-BREF among norwegian substance use disorder patients. BMC Med Res Methodol. 2019;19(1):44.
   PubMed Web of Science ®Google Scholar